or Try an Advanced Search...

    Technical Analysis for ACRV - Acrivon Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 9.48 -5.25% -0.53
    ACRV closed up 18.2 percent on Monday, April 29, 2024, on 26 percent of normal volume.
    Earnings due: May 7
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical ACRV trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish -5.25%
    Outside Day Range Expansion -5.25%
    Wide Bands Range Expansion -5.25%
    20 DMA Resistance Bearish 12.00%
    1,2,3 Pullback Bullish Bullish Swing Setup 12.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 12.00%
    NR7 Range Contraction 12.00%
    Narrow Range Bar Range Contraction 12.00%
    Inside Day Range Contraction 12.00%
    Wide Bands Range Expansion 12.00%
    Older End-of-Day Signals for ACRV ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 1 hour ago
    Down 3% about 1 hour ago
    Fell Below 10 DMA about 1 hour ago
    Down 2 % about 1 hour ago
    Down 1% about 1 hour ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ACRV Chart by TradingView
    Basic chart:

    Profile

    Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops precision oncology medicines. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1/2 for use in the treatment of platinum-resistant ovarian cancer; endometrial and bladder cancer; and SCCs, including SCCHN, cervical, and anal cancer. It is also developing two preclinical drug programs used to predict tumor sensitivity based on custom OncoSignature tests. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Oncology Tumor Ovarian Cancer Bladder Cancer Gynaecological Cancer Anal Cancer

    Is ACRV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
    Apr 17 Acrivon Therapeutics files to sell 15.29M shares of common stock for holders
    Apr 17 Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
    Apr 10 Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resis...
    Apr 9 Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Apr 9 Dow Dips 150 Points; Laser Photonics Shares Spike Higher
    Apr 9 Acrivon Therapeutics stock surges on $130M private placement financing
    Apr 9 Acrivon Therapeutics Announces $130 Million Private Placement Financing
    Mar 30 Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ...
    Mar 28 Acrivon Therapeutics GAAP EPS of -$0.86
    See more ACRV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.3
    52 Week Low 3.19
    Average Volume 939,519
    200-Day Moving Average 7.16
    50-Day Moving Average 6.70
    20-Day Moving Average 8.84
    10-Day Moving Average 9.55
    Average True Range 1.23
    RSI (14) 60.78
    ADX 42.32
    +DI 31.84
    -DI 15.00
    Chandelier Exit (Long, 3 ATRs) 8.22
    Chandelier Exit (Short, 3 ATRs) 9.38
    Upper Bollinger Bands 11.76
    Lower Bollinger Band 5.92
    Percent B (%b) 0.7
    BandWidth 66.02
    MACD Line 0.80
    MACD Signal Line 0.96
    MACD Histogram -0.1541
    Fundamentals Value
    Market Cap 221.94 Million
    Num Shares 22.2 Million
    EPS -2.26
    Price-to-Earnings (P/E) Ratio -4.42
    Price-to-Sales 0.00
    Price-to-Book 0.57
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.97
    Resistance 3 (R3) 12.69 11.42 12.47
    Resistance 2 (R2) 11.42 10.67 11.56 12.31
    Resistance 1 (R1) 10.71 10.20 11.07 10.99 12.14
    Pivot Point 9.45 9.45 9.63 9.59 9.45
    Support 1 (S1) 8.74 8.69 9.09 9.01 7.86
    Support 2 (S2) 7.47 8.23 7.61 7.69
    Support 3 (S3) 6.76 7.47 7.53
    Support 4 (S4) 7.03